Consumer Defensive
Live Price
Offline$0.0007
+0.00% today
1Y Change
+600.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RBC Life Sciences, Inc. (RBCL) is a Consumer Defensive stock with listed on OTC. The stock last traded around $0.00 and up 600.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +5.8%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +5.8%, EPS 0.0%, free cash flow +100.2% with operating margin -2.6% and ROIC -8.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines RBCL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBCL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RBCL Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RBCL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$25.2M
-1.2% YoY
FY Net Income
-$361.4K
+27.7% YoY
Free Cash Flow
-$360.0K
-1424.8% YoY
Revenue Growth
+5.8%
EPS Growth
+0.0%
Gross Margin
52.8%
Net Margin
-2.9%
Income statement
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 26M | 24M | 28M | 25M | 25M |
| Gross Profit | 14M | 13M | 16M | 12M | 13M |
| Operating Income | -666K | -3M | -625K | -625K | -464K |
| EBITDA | -252K | -302K | -45K | -36K | 121K |
| Net Income | -756K | -742K | -603K | -500K | -361K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 1M | 2M | 4M | 4M |
| Total Assets | 11M | 11M | 16M | 18M | 18M |
| Total Liabilities | 4M | 3M | 8M | 9M | 8M |
| Shareholder Equity | 7M | 8M | 8M | 9M | 10M |
| Total Debt | 0 | 0 | 1M | 1M | 2M |
| Net Debt | -1M | -1M | -785K | -2M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
445K
+51.4% YoY
Capital Expenditures
805K
-201.6% YoY
Free Cash Flow
360K
-1424.8% YoY
Key ratios
Gross Margin
52.8%
Operating Margin
-2.6%
Net Margin
-2.9%
ROE
-10.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.